Monogenic (Mendelian): vascular EDS, COL3A1 (rarely COL1A1); ~50% de novo[1]
Ehlers-Danlos Syndrome (Vascular Type)
Quick Summary
Definition: An autosomal dominant COL3A1-related connective tissue disorder with fragility and spontaneous rupture of arteries, bowel and gravid uterus.[1]
- Prevalence: 1 in 50,000-200,000 (MOST LIFE-THREATENING EDS subtype)[1]
- Key gene: COL3A1 (type III collagen defect), autosomal dominant
- Hallmark: Arterial/intestinal/uterine rupture + thin translucent skin + easy bruising + characteristic facies
- High-risk markers: Family history arterial events, pregnancy (uterine rupture risk), ANY arterial dissection/rupture
- First-line Mx: Celiprolol (reduces vascular events), AVOID invasive procedures, emergency surgery only when essential, genetic counseling
Aetiology
Genetics
Inheritance: Autosomal dominant; first-degree relatives have a 50% risk of inheriting the pathogenic variant.[1]
Familial vs de novo: Approximately 50% of vEDS cases are familial (inherited from an affected parent); approximately 50% arise as de novo COL3A1 mutations, no prior family history. This high de novo rate means a negative family history does NOT exclude vEDS.[1]
Gene: COL3A1, encodes type III procollagen; structural defect → arterial, uterine, and intestinal fragility
Prevalence
Vascular EDS (vEDS): 1 in 50,000 to 1 in 200,000[1]
Most life-threatening EDS subtype
Diagnosis
Diagnosis is molecular: vascular EDS is confirmed by a pathogenic COL3A1 variant. Clinical suspicion (the criteria below) should trigger urgent genetic testing rather than invasive investigation.[1]
Major criteria:
- Arterial rupture/dissection
- Intestinal perforation
- Uterine rupture (pregnancy)
- Pneumothorax
Minor features: Thin translucent skin, easy bruising, characteristic facial features, acrogeria (aged appearance of hands)
Investigations
Genetic testing: COL3A1 sequencing (diagnostic; preferred over skin biopsy in the first instance)[1]
Imaging: Use non-invasive arterial imaging (duplex, CT or MR angiography) for surveillance at individualised intervals in expert care. Avoid invasive arteriography and arterial puncture unless clinically essential, because COL3A1 disease carries a significant risk of arterial injury from invasive procedures[2][3]
Treatments
1. General measures:
- Non-invasive arterial imaging (duplex / CT / MR angiography) of the whole arterial tree at individualised intervals[3]
- Patient-held emergency/alert card; avoid contact and high-resistance sports; plan pregnancy and delivery at an expert centre (high risk of arterial and uterine rupture)
- Genetic counselling and family cascade testing, see the Genetic Testing page
2. Medical therapy:
- Celiprolol: first-line; reduced arterial rupture/dissection in a randomised trial. Up-titrate to the maximum tolerated dose.[4]
- Strict blood-pressure control; avoid arterial puncture and elective angiography wherever possible.[3]
3. Surgery:
- Avoid elective surgery where possible, tissue fragility makes haemostasis and repair difficult; conservative or endovascular management is preferred and should be at a centre familiar with vEDS[3]
Complications
- Spontaneous arterial rupture or dissection: of medium-sized vessels, often without a preceding aneurysm, and the leading cause of death[1]
- Hollow-organ rupture: sigmoid colon and gravid uterus, with spontaneous pneumothorax
- Catastrophic procedural and surgical bleeding: with poor wound healing, so intervention itself is hazardous
- High peripartum mortality.
Risk Stratification
Median survival: ~50 years
Pregnancy very high risk. Published mortality estimates vary; GeneReviews cites approximately 5% mortality per pregnancy, depending on variant, vascular history and expert management
Pregnancy Management
Pregnancy in vascular Ehlers-Danlos syndrome - very high risk, not universally forbidden
Pregnancy in vEDS carries a genuinely high risk of arterial, uterine or bowel rupture, but this is not an absolute contraindication and outcomes vary considerably. The largest published series (GeneReviews, pooling multiple cohorts) estimates maternal mortality at around 5% per pregnancy, and roughly half of pregnancies in that series had no major vascular complication. Risk varies by the specific COL3A1 variant and by prior vascular history (previous dissection/rupture carries materially higher risk than no prior vascular event).[1]
Counselling: pre-pregnancy counselling should be non-coercive, patient-led and variant-informed, presenting the realistic range of outcomes (including the substantial proportion without major complication), rather than a uniform worst-case figure. The full range of options, including continuing pregnancy with specialist surveillance, deferring pregnancy, and alternative family-building routes (surrogacy, adoption), should be discussed; the decision belongs to the patient.
If pregnancy occurs or continues: care should be led by a Pregnancy Heart Team / vascular-genetics MDT (cardiology or vascular medicine, vascular surgery, maternal-fetal medicine, clinical genetics, obstetric anaesthesia), with an individualized surveillance plan and 24/7 access to the team for new symptoms. There is no validated evidence that a fixed weekly review schedule or a specific blood-pressure target changes outcome; monitoring intensity should be set by the MDT based on the individual's risk profile.
Delivery planning: the choice between vaginal delivery and caesarean section should weigh the risk of tissue injury from labour and vaginal delivery against the risk of major surgical haemorrhage and organ injury at caesarean section in fragile tissue; caesarean delivery should not be presented as universally safer, and the mode and timing of delivery should be an individualized MDT decision.[5]
Postpartum: the risk of rupture continues into the postpartum period, so continued specialist access and patient education about urgent symptoms (sudden severe pain, signs of haemorrhage) remain important for several weeks after delivery.
Contraception: discuss the full range of options, including long-acting reversible contraception and permanent methods, through non-directive counselling; the decision, including whether to consider a future pregnancy, is led by the patient.
Key Points
- Arterial/bowel rupture can occur spontaneously without warning[1]
- Avoid invasive vascular procedures when possible (tissue fragility)[1]
- Pregnancy is very high risk, not universally contraindicated; the largest series estimates ~5% maternal mortality per pregnancy, with roughly half of pregnancies having no major vascular complication; risk varies by COL3A1 variant and prior vascular history[1]
- Offer early, non-directive, variant-informed reproductive counselling covering all options, including continuing pregnancy with specialist surveillance, surrogacy and adoption
- If pregnancy occurs: manage at a specialist centre; delivery timing and mode are set by the cardio-obstetric MDT
- Offer highly effective contraception (including LARC or sterilisation) to all women of reproductive age, with the decision led by the patient
References & Review Date
Last reviewed: July 2026
- Malfait F, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8–26. doi:10.1002/ajmg.c.31552
- Erbel R, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. 2014;35(41):2873–2926. doi:10.1093/eurheartj/ehu281
- Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases (incl. vascular Ehlers-Danlos arterial surveillance). Eur Heart J. 2024;45:3538–3700. doi:10.1093/eurheartj/ehae179
- Ong KT, Perdu J, De Backer J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010;376(9751):1476–1484. doi:10.1016/S0140-6736(10)60960-9
- 2025 ESC Guidelines for the management of cardiovascular disease during pregnancy. Eur Heart J. 2025. doi:10.1093/eurheartj/ehaf193